Radiolabeled Peptide as Diagnostic, Therapeutic, and Theranostic agents for Prostate Cancer: Systematic Literature Review

Effendi, Nurmaya (2022) Radiolabeled Peptide as Diagnostic, Therapeutic, and Theranostic agents for Prostate Cancer: Systematic Literature Review. Pharmaceutical Reports, 1 (1). pp. 23-28. ISSN 2828-8734

	Text Pharm_Rep_March_2022_Article.pdf Download (278kB)
	Text PR_2022_Corresponding Letter.pdf Download (143kB)

Abstract

Prostate cancer (PCa) is the most common sex-related malignancy and the second most common cause of mortality
after lung cancer for men. Around 61.8% of Indonesian people undergo cancer treatment with surgery. This study aimed to figure
out the use of radiolabeled peptides for diagnosis, therapy, and theranostics of prostate cancer. This study performed a literature
review by searching the web databases such as PubMed, MDPI, Elsevier (Science Direct), and ACS Publications. The result showed
that peptide compounds such RM2, VCN (Vicrostatin), DB15, and BBN7-14 were utilized as radionuclide-carriers for diagnostic
imaging, meanwhile, peptides such as NeoBOMB1, PSMA-617, and [RGD-Glu-[DO3A]-6-Ahx-RM2] containing alpha or betaemitted radionuclide were used as therapeutic and theranostic agents. They were tagged using 68Ga, 161Tb, 177Lu, 64Cu, 124I, 99mTc,
90Y, and 86Y radionuclides. Great efforts have been conducted in developing peptide-based radiopharmaceuticals for diagnosis and
therapy of prostate cancer. Research groups focusing in nuclear medicine will continue to develop radiopharmaceuticals in the
future, especially radiopeptide compounds for the diagnosis and therapy of prostate cancer.

Item Type:	Article
Uncontrolled Keywords:	Radiolabelled-peptide; therapy; diagnosis; prostate cancer.
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	FAKULTAS FARMASI
Depositing User:	Admin Admin
Date Deposited:	26 May 2023 05:37
Last Modified:	26 May 2023 05:37
URI:	http://192.168.168.84/id/eprint/2543

Actions (login required)

View Item